Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

2.
3.

Topors acts as a SUMO-1 E3 ligase for p53 in vitro and in vivo.

Weger S, Hammer E, Heilbronn R.

FEBS Lett. 2005 Sep 12;579(22):5007-12.

4.

The topoisomerase I-binding RING protein, topors, is associated with promyelocytic leukemia nuclear bodies.

Rasheed ZA, Saleem A, Ravee Y, Pandolfi PP, Rubin EH.

Exp Cell Res. 2002 Jul 15;277(2):152-60.

PMID:
12083797
5.

P300 transcriptional repression is mediated by SUMO modification.

Girdwood D, Bumpass D, Vaughan OA, Thain A, Anderson LA, Snowden AW, Garcia-Wilson E, Perkins ND, Hay RT.

Mol Cell. 2003 Apr;11(4):1043-54.

6.
7.

SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation.

Duprez E, Saurin AJ, Desterro JM, Lallemand-Breitenbach V, Howe K, Boddy MN, Solomon E, de Thé H, Hay RT, Freemont PS.

J Cell Sci. 1999 Feb;112 ( Pt 3):381-93.

8.

The E3 ligase Topors induces the accumulation of polysumoylated forms of DNA topoisomerase I in vitro and in vivo.

Hammer E, Heilbronn R, Weger S.

FEBS Lett. 2007 Nov 27;581(28):5418-24. Epub 2007 Oct 30.

9.

ZNF198, a zinc finger protein rearranged in myeloproliferative disease, localizes to the PML nuclear bodies and interacts with SUMO-1 and PML.

Kunapuli P, Kasyapa CS, Chin SF, Caldas C, Cowell JK.

Exp Cell Res. 2006 Nov 15;312(19):3739-51. Epub 2006 Aug 14.

PMID:
17027752
10.

Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53.

Rajendra R, Malegaonkar D, Pungaliya P, Marshall H, Rasheed Z, Brownell J, Liu LF, Lutzker S, Saleem A, Rubin EH.

J Biol Chem. 2004 Aug 27;279(35):36440-4. Epub 2004 Jul 9.

12.

A Kruppel zinc finger of ZNF 146 interacts with the SUMO-1 conjugating enzyme UBC9 and is sumoylated in vivo.

Antoine K, Prosperi MT, Ferbus D, Boule C, Goubin G.

Mol Cell Biochem. 2005 Mar;271(1-2):215-23.

PMID:
15881673
13.
14.

Perturbation of SUMOlation enzyme Ubc9 by distinct domain within nucleoporin RanBP2/Nup358.

Saitoh H, Pizzi MD, Wang J.

J Biol Chem. 2002 Feb 15;277(7):4755-63. Epub 2001 Nov 14.

15.

PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1.

Ishov AM, Sotnikov AG, Negorev D, Vladimirova OV, Neff N, Kamitani T, Yeh ET, Strauss JF 3rd, Maul GG.

J Cell Biol. 1999 Oct 18;147(2):221-34.

16.

Identification of phosphorylation sites of TOPORS and a role for serine 98 in the regulation of ubiquitin but not SUMO E3 ligase activity.

Park HJ, Zheng H, Kulkarni D, Kerrigan J, Pungaliya P, Saleem A, Rubin EH.

Biochemistry. 2008 Dec 30;47(52):13887-96. doi: 10.1021/bi801904q.

PMID:
19053840
17.

Transcription factor AP-2 interacts with the SUMO-conjugating enzyme UBC9 and is sumolated in vivo.

Eloranta JJ, Hurst HC.

J Biol Chem. 2002 Aug 23;277(34):30798-804. Epub 2002 Jun 18.

18.

Heat shock and Cd2+ exposure regulate PML and Daxx release from ND10 by independent mechanisms that modify the induction of heat-shock proteins 70 and 25 differently.

Nefkens I, Negorev DG, Ishov AM, Michaelson JS, Yeh ET, Tanguay RM, Müller WE, Maul GG.

J Cell Sci. 2003 Feb 1;116(Pt 3):513-24.

19.

UHRF2, a ubiquitin E3 ligase, acts as a small ubiquitin-like modifier E3 ligase for zinc finger protein 131.

Oh Y, Chung KC.

J Biol Chem. 2013 Mar 29;288(13):9102-11. doi: 10.1074/jbc.M112.438234. Epub 2013 Feb 12.

20.

SUMO-1 modification of the Wilms' tumor suppressor WT1.

Smolen GA, Vassileva MT, Wells J, Matunis MJ, Haber DA.

Cancer Res. 2004 Nov 1;64(21):7846-51.

Supplemental Content

Support Center